However, when PD-1 or PD-L1 plus bevacizumab were compared with sorafenib, the risk of developing rash was lower than that of the control group (OR = 0.13, 95% CI: [0.02, 0.83]; I2 = 0%, Z = 2.16, p=0.03; Figure 6(h)). This evidence concerns the gene PDCD1 and Skin rash.